MSLN and neoplasm: As shown in Figure 3B,C, consistent with the results observed by subcutaneous tumors, the tumors in the MSLN antibody treatment alone or the PanNV treatment alone, although have a certain tumor growth inhibition compared to the PBS treatment, but correspondingly showed a significantly increase of tumor burden compared with that in DAY0.